In clinical studies, hepatic IL-6 was increased in patients with biopsy-proven NASH compared to those with hepatic steatosis or controls and was associated with the severity of the disease [190]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.